Disease Information

General Information of the Disease (ID: DIS00334)
Name
Osteoporosis
ICD
ICD-11: FB83
Type(s) of Resistant Mechanism of This Disease
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Drug
Approved Drug(s)
1 drug(s) in total
Click to Show/Hide the Full List of Drugs
Matrine
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: TNF superfamily member 11 (TNFSF11) [1]
Sensitive Disease Osteoporosis [ICD-11: FB83.1]
Molecule Alteration Expression
Down-regulation
 Molecule Info 
Sensitive Drug Matrine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation NF-kappaB signaling pathway Inhibition hsa04064
AKT signaling pathway Inhibition hsa04151
MAPK signaling pathway Inhibition hsa04010
In Vitro Model RAW264.7 cells Ascites Mus musculus (Mouse) CVCL_0493
In Vivo Model C57BL/6 mice Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 TRAP staining assay
Mechanism Description The imbalance between the osteogenic effects of osteoblasts and the osteoclasts of osteoclasts is one of the pathogenesis of postmenopausal osteoporosis. Secretion of estrogen causes an increase in the level of proinflammatory cytokines. Inflammation-induced osteoclast hyperactivity plays a crucial role in the imbalance. Matrine can inhibit osteoclastogenesis, inhibit inflammation and alleviate osteoporosis by regulating the NF-kappa-B/AKT/MAPK pathway.
Key Molecule: TNF superfamily member 11 (TNFSF11) [1]
Sensitive Disease Osteoporosis [ICD-11: FB83.1]
Molecule Alteration Expression
Down-regulation
 Molecule Info 
Sensitive Drug Matrine
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Cell Pathway Regulation NF-kappaB signaling pathway Inhibition hsa04064
AKT signaling pathway Inhibition hsa04151
MAPK signaling pathway Inhibition hsa04010
In Vitro Model RAW264.7 cells Ascites Mus musculus (Mouse) CVCL_0493
In Vivo Model C57BL/6 mice Mus musculus
Experiment for
Molecule Alteration		 Western blotting analysis
Experiment for
Drug Resistance		 TRAP staining assay
Mechanism Description The imbalance between the osteogenic effects of osteoblasts and the osteoclasts of osteoclasts is one of the pathogenesis of postmenopausal osteoporosis. Secretion of estrogen causes an increase in the level of proinflammatory cytokines. Inflammation-induced osteoclast hyperactivity plays a crucial role in the imbalance. Matrine can inhibit osteoclastogenesis, inhibit inflammation and alleviate osteoporosis by regulating the NF-kappa-B/AKT/MAPK pathway.
References
Ref 1 Matrine: A Promising Natural Product With Various Pharmacological Activities .Front Pharmacol. 2020 May 7;11:588. doi: 10.3389/fphar.2020.00588. eCollection 2020. 10.3389/fphar.2020.00588

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.